Leptospira interrogans serovar Icterohaemorrhagiae antigens

Leptospira interrogans serovar Icterohaemorrhagiae antigens represent the complex array of surface-exposed molecules, primarily lipopolysaccharides (LPS) and lipoproteins such as LipL32 and Loa22, that define the immunological profile of this highly pathogenic spirochete (Haake & Levett, 2015). These antigens are the primary targets for the host's immune system and are central to the development of serovar-specific vaccines, which aim to elicit high titers of agglutinating antibodies to prevent infection (Adler, 2015). In clinical practice, these antigens are utilized in the Microscopic Agglutination Test (MAT), the gold standard for diagnosing leptospirosis by detecting serovar-specific antibody responses (WHO, 2003). The Icterohaemorrhagiae serovar is particularly significant as it is the most common cause of Weil's disease, a severe form of leptospirosis characterized by jaundice, renal failure, and hemorrhage (StatPearls, 2023). While therapeutic intervention typically involves broad-spectrum antibiotics like doxycycline or penicillin that target bacterial viability, the antigens themselves are the focus of research into recombinant subunit vaccines and monoclonal antibody therapies designed to provide targeted protection and rapid diagnostic capabilities.

Other names

Leptospira interrogans serogroup Icterohaemorrhagiae antigensWeil's disease antigensLeptospiral surface antigensL. interrogans serovar Icterohaemorrhagiae surface proteins

Vaccines utilize these antigens to stimulate B-lymphocytes to produce serovar-specific neutralizing antibodies (IgM and IgG) that facilitate bacterial opsonization and clearance by phagocytes (Adler, 2015). Antibiotics used during infection inhibit bacterial protein synthesis or cell wall assembly, leading to the release of these antigens and subsequent immune activation.